Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
STK11
REST API REST API
Homo sapiens
STK11 is differentially expressed in 270 experiments: 132 organism parts: liver, testis, ... (130 more);, 196 disease states: normal, chronic myelogenous leukemia, ... (194 more);, 80 cell types 366 cell lines 35 compound treatments and 74 other conditions.
Synonyms LKB1, PJS
Orthologs STK11 (Gallus gallus)   Stk11 (Rattus norvegicus)   stk11 (Danio rerio)   STK11 (Bos taurus)   Stk11 (Mus musculus)   ENSCING00000006359 (Ciona intestinalis)   lkb1 (Drosophila melanogaster)   SAK1 (Saccharomyces cerevisiae)   TOS3 (Saccharomyces cerevisiae)   stk11 (Xenopus laevis)   STK11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term establishment of cell polarity, cytosol, negative regulation of cell growth, protein binding, cytoplasm, negative regulation of cell proliferation, protein complex, membrane, cell cycle arrest, protein tyrosine kinase activity, insulin receptor signaling pathway, positive regulation of transforming growth factor beta receptor signaling pathway, glucose homeostasis, regulation of fatty acid biosynthetic process, response to ionizing radiation, ATP binding, cell cycle, magnesium ion binding, nucleus, canonical Wnt receptor signaling pathway, spermatid development, regulation of Wnt receptor signaling pathway, nucleotide binding, regulation of cell growth, protein serine/threonine kinase activity, axonogenesis, tissue homeostasis, response to DNA damage stimulus, autophagy, protein kinase activity, mitochondrion, positive regulation of axonogenesis, energy reserve metabolic process, negative regulation of epithelial cell proliferation involved in prostate gland development, protein kinase activator activity, LRR domain binding, vasculature development, regulation of fatty acid oxidation, response to peptide hormone stimulus, response to lipid, positive regulation of gluconeogenesis, p53 binding, regulation of protein kinase B signaling cascade, Golgi localization, response to glucagon stimulus, protein heterooligomerization, protein autophosphorylation, protein phosphorylation, positive regulation of protein phosphorylation, signal transduction by p53 class mediator resulting in induction of apoptosis, anoikis
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q15831, Q9NS52
Gene-Disease Assocation TESTICULAR TUMORS, PEUTZ-JEGHERS SYNDROME; PJS
Search EB-eye ENSG00000118046
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
SNU16
2
E-GEOD-15460, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
MCF-10A
2
E-TABM-420, E-GEOD-14990
NCIH810
1
E-MTAB-37
360 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-19397, E-GEOD-13909, E-GEOD-20677, ... (42 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-19240, E-GEOD-3998
Monocytes
1
E-GEOD-21909
hematopoietic stem cell
1
E-MEXP-872
induced pluripotent stem cell
1
E-GEOD-18147
CXCR4 positive
1
E-GEOD-15893
basal cell
1
E-GEOD-3998
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (59 experiments)

Factor Value U/D Experiments
adenocarcinoma
2
E-MTAB-37, E-MEXP-1331
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
190 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-3720, ... (23 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5824, E-GEOD-2803, E-GEOD-412, E-GEOD-20719, E-MEXP-1958, ... (9 experiments)
PGE2
1
1
E-MEXP-1230
mercaptopurine, methotrexate
1
E-GEOD-412
control for heregulin
1
E-GEOD-6462
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-3013

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-MEXP-1103, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-10433, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.455 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM